Research Analysts’ updated eps estimates for Wednesday, October 4th:

Adamas Pharmaceuticals (NASDAQ:ADMS) had its overweight rating reissued by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $30.00 target price on the stock.

Mizuho began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA). Mizuho issued a buy rating on the stock.

Antero Midstream GP (NASDAQ:AMGP) had its hold rating reaffirmed by analysts at Scotiabank. They currently have a $24.00 price target on the stock.

Bravo Brio Restaurant Group (NASDAQ:BBRG) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Bravo Brio Restaurant Group, Inc. is an owner and operator of two distinct Italian restaurant brands, BRAVO! Cucina Italiana and BRIO Tuscan Grille. BRAVO! Cucina Italiana is a full-service, upscale Italian restaurant offering a menu of freshly prepared classic Italian food. BRAVO offers variety of pasta dishes, steaks, chicken, seafood and pizzas. It also offers seasonal specials, an extensive wine list, carry-out and catering. BRIO Tuscan Grille is an upscale Italian chophouse restaurant serving authentic northern Italian food in a Tuscan Villa atmosphere. The cuisine at BRIO includes steaks, chops, fresh seafood and made-to-order pastas. BRIO also offers creative seasonal specials, an extensive wine list, and carry-out and banquet facilities at select locations. It also operates one full-service upscale American-French bistro restaurant in Columbus, Ohio under the brand Bon Vie. Bravo Brio Restaurant Group is based in Columbus, Ohio. “

Sotheby’s (NYSE:BID) was upgraded by analysts at Consumer Edge from a neutral rating to an overweight rating.

Bio-Rad Laboratories (NYSE:BIO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. “

Benefitfocus (NASDAQ:BNFT) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Benefitfocus, Inc. offers cloud-based software solutions to consumers, employers, insurance carriers and brokers. The Company’s platform of products and services enable customers to efficiently shop, enroll, manage and exchange benefits information. Benefitfocus, Inc. is based in Charleston, South Carolina. “

BofI Holding (NASDAQ:BOFI) had its buy rating reaffirmed by analysts at Craig Hallum. They currently have a $39.00 target price on the stock, up from their previous target price of $35.00.

CalAmp Corp. (NASDAQ:CAMP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “CalAmp Corp. is a leading provider of wireless communications products that enable anytime/anywhere access to critical information, data and entertainment content. With comprehensive capabilities ranging from product design and development through volume production, CalAmp delivers cost-effective high quality solutions to a broad array of customers and end markets. CalAmp is the leading supplier of Direct Broadcast Satellite outdoor customer premise equipment to the U.S. satellite television market. The Company also provides wireless data communication solutions for the telemetry and asset tracking markets, private wireless networks, public safety communications and critical infrastructure and process control applications. “

Cara Therapeutics (NASDAQ:CARA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. “

Cancer Genetics (NASDAQ:CGIX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company’s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. “

Comtech Telecommunications Corp. (NASDAQ:CMTL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $22.00 price target on the stock. According to Zacks, “Comtech Telecommunications Corp. designs and produces a wide range of telecom systems and services. The company’s telecom transmission division markets such products as satellite earth station equipment and over-the-horizon microwave systems. The mobile data communications department offers mobile satellite transceivers and satellite packet data networks. Comtech also manufactures broadband amplifiers in the microwave and radio frequency spectrums. Its amplifiers are used in both defense and commercial applications. It offers communications solutions, including command and control technologies, safety and security technologies and enterprise technologies. Its Commercial Solutions segment provides satellite communications (such as satellite earth station modems and traveling wave tube amplifiers), public safety systems (such as next generation 911 technologies) and enterprise application technologies (such as messaging and trusted location-based technologies. “

CONSOL Energy (NYSE:CNX) had its hold rating reissued by analysts at Scotiabank.

Crown Media Holdings (NASDAQ:CRWN) had its target price lowered by Raymond James Financial, Inc. from $12.00 to $11.50. The firm currently has an outperform rating on the stock.

CoStar Group (NASDAQ:CSGP) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CoStar Group, Inc. provides information services to the commercial real estate industry. Their wide array of digital service offerings includes a leasing marketplace, a selling marketplace, sales comparable information, decision support, contact management, tenant information, property marketing, and industry news. They have three assets that provide a unique foundation for this marketplace: comprehensive national databases; large research department; and large number of participating organizations. “

Caesarstone (NASDAQ:CSTE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $34.00 price target on the stock. According to Zacks, “CaesarStone Ltd manufactures engineered quartz surfaces for residential and commercial buildings as countertops, vanities, wall cladding, floors and other interior surfaces. The company’s product consists of Classico, Supernatural, Motivo and Concetto. CaesarStone Ltd, formerly known as Caesarstone Sdot-Yam Ltd., is based in MP Menashe, Israel. “

CVR Refining, (NYSE:CVRR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $11.00 target price on the stock. According to Zacks, “CVR Refining, LP is engaged in the refining of petroleum primarily in the United States. It has refining and related logistics assets that operate in the mid-continent region. The company operates in Coffeyville, Kansas, Wynnewood and Oklahoma. CVR Refining, LP is headquartered in Sugar Land, Texas. “

Cemex S.A.B. de C.V. (NYSE:CX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CEMEX is one of the largest cement companies in the world, with close to 78 million metric tons of production capacity. Through operating subsidiaries in four continents, they are engaged in the production, distribution, marketing and sale of cement, ready-mix concrete, aggregates and clinker. They are also the world’s leading producer of white cement and the world’s largest trader of cement and clinker. “

Delta Air Lines (NYSE:DAL) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $57.00 target price on the stock, up from their previous target price of $56.00.

Diplomat Pharmacy (NYSE:DPLO) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $23.75 target price on the stock, up from their previous target price of $19.75.

Equifax (NYSE:EFX) had its equal weight rating reiterated by analysts at Stephens. The firm currently has a $110.00 price target on the stock.

EQT GP Holdings, (NYSE:EQGP) had its hold rating reiterated by analysts at Scotiabank. The firm currently has a $32.00 target price on the stock.

EQT (NYSE:EQT) had its average rating reissued by analysts at Scotiabank. Scotiabank currently has a $79.00 target price on the stock.

Etsy (NASDAQ:ETSY) had its neutral rating reiterated by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $14.50 target price on the stock.

East West Bancorp (NASDAQ:EWBC) had its equal weight rating reaffirmed by analysts at Morgan Stanley. They currently have a $63.00 price target on the stock, up from their previous price target of $61.00.

Mizuho initiated coverage on shares of FibroGen (NASDAQ:FGEN). Mizuho issued a neutral rating on the stock.

First Horizon National Corporation (NYSE:FHN) had its equal weight rating reaffirmed by analysts at Morgan Stanley. They currently have a $20.00 target price on the stock, up from their previous target price of $19.50.

Amicus Therapeutics (NASDAQ:FOLD) had its outperform rating reiterated by analysts at Robert W. Baird. The firm currently has a $18.00 target price on the stock, up from their previous target price of $16.00.

Amicus Therapeutics (NASDAQ:FOLD) had its overweight rating reaffirmed by analysts at J P Morgan Chase & Co.

Intelsat (NYSE:I) had its buy rating reaffirmed by analysts at Jefferies Group LLC. Jefferies Group LLC currently has a $5.00 price target on the stock.

IAC/InterActiveCorp (NASDAQ:IAC) had its overweight rating reissued by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $160.00 price target on the stock, up from their previous price target of $152.00.

J.B. Hunt Transport Services (NASDAQ:JBHT) had its buy rating reaffirmed by analysts at Loop Capital. They currently have a $116.00 target price on the stock, up from their previous target price of $103.00.

JetBlue Airways Corporation (NASDAQ:JBLU) had its equal weight rating reaffirmed by analysts at Morgan Stanley. They currently have a $20.00 price target on the stock, down from their previous price target of $21.00.

Mplx Lp (NYSE:MPLX) had its buy rating reiterated by analysts at Scotiabank. They currently have a $44.00 target price on the stock.

Match Group (NASDAQ:MTCH) had its overweight rating reaffirmed by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $28.00 target price on the stock, up from their previous target price of $25.00.

Mylan N.V. (NASDAQ:MYL) had its market perform rating reiterated by analysts at Wells Fargo & Company. Wells Fargo & Company currently has a $32.00 price target on the stock, up from their previous price target of $30.00.

Netflix (NASDAQ:NFLX) had its overweight rating reissued by analysts at Piper Jaffray Companies. They currently have a $215.00 target price on the stock.

NuVasive (NASDAQ:NUVA) had its buy rating reiterated by analysts at BTIG Research. The firm currently has a $74.00 price target on the stock, down from their previous price target of $82.00.

William Blair began coverage on shares of Okta (NASDAQ:OKTA). William Blair issued an outperform rating on the stock.

Paychex (NASDAQ:PAYX) had its equal weight rating reiterated by analysts at Morgan Stanley. They currently have a $59.00 target price on the stock, up from their previous target price of $55.00.

The Priceline Group (NASDAQ:PCLN) had its buy rating reissued by analysts at SunTrust Banks, Inc.. The firm currently has a $2,200.00 price target on the stock.

Quotient Technology (NYSE:QUOT) had its buy rating reaffirmed by analysts at Dougherty & Co. The firm currently has a $20.00 price target on the stock, up from their previous price target of $16.00.

Rice Energy (NYSE:RICE) had its hold rating reissued by analysts at Scotiabank. Scotiabank currently has a $27.00 target price on the stock.

SVB Financial Group (NASDAQ:SIVB) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $213.00 price target on the stock, up from their previous price target of $210.00.

KeyCorp initiated coverage on shares of U.S. Silica Holdings (NYSE:SLCA). They issued an overweight rating on the stock.

Viper Energy Partners (NASDAQ:VNOM) had its in-line rating reiterated by analysts at Imperial Capital. The firm currently has a $23.00 price target on the stock, up from their previous price target of $21.00.

Wayfair (NYSE:W) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $82.00 target price on the stock.

Xylem (NYSE:XYL) had its outperform rating reissued by analysts at Royal Bank Of Canada. They currently have a $71.00 target price on the stock, up from their previous target price of $64.00.

Zions Bancorporation (NASDAQ:ZION) had its equal weight rating reiterated by analysts at Morgan Stanley. They currently have a $49.00 target price on the stock, up from their previous target price of $48.00.

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.